Answer
The most common adverse effects of zanubrutinib monotherapy (≥20%) are upper respiratory tract infection (36%), bruising (32%), haemorrhage/haematoma (30%), neutropenia (30%), musculoskeletal pain (27%), rash (25%), pneumonia (24%), diarrhoea (21%) and cough (21%).
Sources for this answer
- BRUKINSA 80 mg hard capsulesBeOne Medicines UK, Ltd. · emc · SmPC §4.8 Undesirable effects · Version 8Document updated
Sources checked